World journal of urology · 2026
Outcomes of patients undergoing Optilume® drug-coated balloon for different locations of urethral strictures: results from a multicenter cohort.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seiler Lea, De Giorgi Giovanni Lorenzo, Mantica Guglielmo, Karapanos Leonidas, Viktorin Pascal, Ahmed Yusuf, Clements Sarah, Güdemann Alexander, Jonusaite Daniele, Gerritsen Kerem, Subotic Svetozar, Kwiatkowski Maciej, Sauer Andreas, Wyler Stephen, Afferi Luca
Аннотация
INTRODUCTION AND OBJECTIVES: The Optilume® drug-coated balloon (DCB), combining mechanical dilation with localized paclitaxel delivery, is a novel minimally invasive treatment for urethral stricture disease. However, data on its effectiveness across different stricture locations are limited. This study evaluates functional outcomes following treatment for different strictures locations.
MATERIALS AND METHODS: This retrospective multicenter study included patients treated with Optilume® DCB for urethral strictures at five European tertiary care referral centers (June 2023 - June 2025). Stricture length was assessed by retrograde urethrography, cystoscopy, or both. Recurrence was defined as any symptomatic stricture requiring treatment. A multivariable logistic regression using preoperative data was developed to predict recurrence requiring treatment.
RESULTS: In total 86 patients were included across four stricture locations: penile (n = 11, 13%), bulbar/penobulbar (n = 59, 68%), bulbomembranous/membranous (n = 13, 15%) and bladder neck (n = 3, 4%). Postoperative complications within 30 days occurred in 5 (5.8%) patients. Median follow-up duration ranged from 3 to 11 months. Median peak urinary flow increased from 3.5 to 8.8 mL/s preoperatively to 13.5-19 mL/s at 3 months. Stricture-free rates were highest in penile (91%) and bladder neck (100%) strictures, and lower for bulbar (74%) and bulbomembranous/membranous (69%) strictures. On multivariate logistic regression analysis, diabetes was an independent predictor of stricture recurrence (OR = 7.66, 95% CI 1.55-47.12, p = 0.01).
CONCLUSIONS: Optilume® DCB showed encouraging efficacy and safety across different urethral stricture locations, achieving high stricture-free rates and improved urinary flow. Diabetes independently predicted recurrence, highlighting the value of optimizing modifiable risk factors.
MATERIALS AND METHODS: This retrospective multicenter study included patients treated with Optilume® DCB for urethral strictures at five European tertiary care referral centers (June 2023 - June 2025). Stricture length was assessed by retrograde urethrography, cystoscopy, or both. Recurrence was defined as any symptomatic stricture requiring treatment. A multivariable logistic regression using preoperative data was developed to predict recurrence requiring treatment.
RESULTS: In total 86 patients were included across four stricture locations: penile (n = 11, 13%), bulbar/penobulbar (n = 59, 68%), bulbomembranous/membranous (n = 13, 15%) and bladder neck (n = 3, 4%). Postoperative complications within 30 days occurred in 5 (5.8%) patients. Median follow-up duration ranged from 3 to 11 months. Median peak urinary flow increased from 3.5 to 8.8 mL/s preoperatively to 13.5-19 mL/s at 3 months. Stricture-free rates were highest in penile (91%) and bladder neck (100%) strictures, and lower for bulbar (74%) and bulbomembranous/membranous (69%) strictures. On multivariate logistic regression analysis, diabetes was an independent predictor of stricture recurrence (OR = 7.66, 95% CI 1.55-47.12, p = 0.01).
CONCLUSIONS: Optilume® DCB showed encouraging efficacy and safety across different urethral stricture locations, achieving high stricture-free rates and improved urinary flow. Diabetes independently predicted recurrence, highlighting the value of optimizing modifiable risk factors.